Business Wire

25 Years of Making the World a Better Place for Women: Mary Kay Ash FoundationSM Marks Milestone Anniversary

Share

In celebration of its 25th anniversary and guided by Mary Kay Ash’s dream to enrich the lives of women worldwide, the Mary Kay Ash FoundationSM released its first-ever Foundation Annual Report, as well as a new name, logo website and rebranding. Since 1996, the Foundation has contributed more than $80 million to organizations aligned with its two-fold mission: funding research for cancers affecting women and ending domestic violence and gender-based violence against women and girls.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005237/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Mary Kay Ash Foundation℠ logo (Graphic: Mary Kay Inc.)

For more than two decades, the Foundation has continued to innovate as a global charitable leader focused on women. To commemorate its milestone anniversary, the organization made a slight name change from The Mary Kay FoundationSM to Mary Kay Ash FoundationSM to improve search engine optimization. In addition, the Foundation unveiled a new logo and website, rebranding and the first-ever Mary Kay Ash FoundationSM Annual Report. The report gives an overview of the 2020 initiatives in the United States and around the world. Key findings in the report include:

  • In 2020, the Mary Kay Ash FoundationSM awarded grants totaling $1,825,000 to causes in the U.S. and those that will make a difference throughout the world via the Innovative/Translational Cancer Research Grants and the International Post-Doctoral Fellowship Cancer Research Program. Since 1996, the Mary Kay Ash FoundationSM has supported innovative cancer research and clinical trials to find a cure for cancers affecting women by awarding more than $25 million for over 250 cutting-edge projects at leading medical schools and research institutions worldwide.
  • Due to the COVID-19 pandemic, a devastating increase was reported in domestic violence across the world in 2020. This pandemic within a pandemic stretched domestic violence shelters to their limits. The Mary Kay Ash FoundationSM awarded emergency grants totaling $1,000,000 to support domestic violence frontline workers – the first responders for women and children. In an effort to expand a global commitment to eradicate gender-based domestic violence, Mary Kay Inc. and the Mary Kay Ash FoundationSM joined forces with the United Nations Trust Fund to End Violence Against Women and CARE USA, humanitarian global leaders. Since 2000, the Foundation has donated more than $58 million to ending gender-based violence. The effort has supported over six million women and girls seeking shelter and services from abuse.

“Twenty-five years ago, my grandmother, Mary Kay Ash, created the Foundation that continues to remain at the heart of Mary Kay Inc., company employees and independent beauty consultants who strive to uphold her vision of making the world a better place for women and their families,” said Ryan Rogers, Chief Investment Officer and Vice President of the Mary Kay Ash FoundationSM Board of Directors. “While the Mary Kay Ash FoundationSM planted its roots in Texas and watched them spread across the United States, much like the company itself, the work of the Foundation knows no borders. We envision a world where women are empowered, healthy and safe. On this milestone anniversary, we continue our steadfast commitment to women worldwide and are reminded of how truly honored we are to continue doing my grandmother’s work.”

For more information, visit marykayashfoundation.org.

About the Mary Kay Ash FoundationSM

Guided by Mary Kay Ash’s dream to enrich the lives of women everywhere, the Mary Kay Ash FoundationSM raises and distributes funds to invest in breakthrough cancer research to find a cure for women-related cancers and ending domestic violence against women. Since 1996, the Mary Kay Ash FoundationSM has contributed more than $80 million to organizations aligned with its two-fold mission. In addition, the Foundation supports awareness initiatives, community outreach programs, and advocates for legislation to ensure women are healthy and safe. Together, we can make the world better for women. To learn more about how to educate, advocate, volunteer and donate, and join life-saving work to support and empower women, visit marykayashfoundation.org, find us on Facebook and Instagram, or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye